ZEVRA THERAPEUTICS INC. - COMMON STOCK

9,5850

22-ноября-24 16:44:58

15 мин. задержка

Акции

+0,4550

+4,98%

Сегодняшний диапазон

9,1500 - 9,6400

ISIN

N/A

Источник

NASDAQ

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting

03 июн 2024 11:00:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Participate at Upcoming Investor Events

09 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

08 май 2024 07:00:01 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024

01 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

29 апр 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting

15 апр 2024 17:01:44 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility

10 апр 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

28 мар 2024 16:32:04 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

26 мар 2024 16:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

25 мар 2024 16:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024

18 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

04 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Participate at Upcoming Investor Conferences

28 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors

23 янв 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

08 янв 2024 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer

04 янв 2024 08:55:49 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

27 дек 2023 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company

20 ноя 2023 07:30:00 Источник Nasdaq GlobeNewswire
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results

07 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.